Summary

The global PD-1 and PD-L1 Monoclonal Antibodies market is projected to grow from US$ 1634 million in 2025 to US$ 2684 million by 2032, at a CAGR of 7.7% (2026-2032), driven by critical product segments and diverse end‑use applications.
PD-1 and PD-L1 monoclonal antibodies are a class of immune checkpoint inhibitors that activate the body's own T cells to kill tumor cells by blocking the signaling pathways of programmed cell death protein 1 (PD-1) or its ligand (PD-L1); they have become standard therapies for various solid tumors and hematological malignancies. In 2025, global sales volume reached approximately 3.8 million vials, with an average price of about $430 per vial based on standard treatment regimens—a figure reflecting global price disparities and the impact of biosimilars—while capacity utilization stood at approximately 83%. Upstream players include culture media manufacturers such as Thermo Fisher and Merck; Protein A affinity chromatography resin suppliers like Cytiva and Nanomicro; and single-use bioreactor provider Sartorius. Downstream entities include hospital pharmacies, oncology clinics, and distributors such as McKesson and Shanghai Pharmaceuticals, with gross margins generally maintained at a high level of 88% to 92%. The product cost structure comprises direct raw materials (e.g., serum-free media, chromatography media, and buffers) at approximately 22%; fixed asset depreciation and cleanroom facilities at 18%; R&D amortization and registration expenses at 35%; and sales, administrative, and channel costs at 15%. Regarding demand and business opportunities, downstream applications cover first-line and adjuvant indications such as non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, Hodgkin lymphoma, bladder cancer, esophageal cancer, and head and neck squamous cell carcinoma; key downstream clients include MD Anderson Cancer Center, Peking Union Medical College Hospital, Sinopharm Group, and Ali Health. Policy drivers include the inclusion of more PD-1 drugs in standard reimbursement lists following Chinese medical insurance negotiations and accelerated review pathways by global regulatory agencies. Technological innovation is evident in subcutaneous formulations, bispecific antibodies (e.g., PD-1/VEGF), and novel therapies combining PD-1 inhibitors with antibody-drug conjugates (ADCs). Finally, shifting consumer demands—with patients seeking longer survival, less frequent infusions, and reduced side effects like hair loss—are fueling interest in the development of long-acting injectables and oral formulations.
The PD-1 and PD-L1 monoclonal antibody market has transitioned from a phase of unchecked expansion to one of maturity and differentiation; while sales volumes continue to rise rapidly, prices are steadily declining due to biosimilars and national reimbursement negotiations, reflecting a strategy of trading price for volume. In the Chinese market, four domestic PD-1 products—from Junshi Biosciences, Innovent Biologics, BeiGene, and Hengrui Medicine—command over 70% of the market share, while imported drugs Keytruda (K-drug) and Opdivo (O-drug) maintain a high-end market stronghold by expanding into indications for early-stage cancer. The average unit price has dropped from tens of thousands of dollars in 2019 to the current national reimbursement price of approximately 3,000 RMB, and the global average price has fallen to $430 due to biosimilar penetration in India and Southeast Asia. A race to expand production capacity has left some companies with utilization rates of only 60%, whereas firms possessing high-expression cell lines and single-use bioreactor technologies maintain utilization rates exceeding 85% alongside lower costs. Future commercial opportunities lie in combination therapies and perioperative treatments; combinations involving PD-1 with chemotherapy, TIGIT, LAG-3, or ADCs are pushing new indications into the first-line setting, thereby extending treatment duration and expanding the patient base. Subcutaneous formulations, which reduce administration time to five minutes and significantly improve patient compliance, are emerging as a key tool for differentiation. On the policy front, the inclusion of early cancer screening in China’s "Healthy China 2030" agenda and the adoption of value-based (efficacy-linked) payment models in Europe and the US are driving higher penetration rates for PD-1 drugs. Furthermore, the expansion of indications into early-stage neoadjuvant and adjuvant settings has significantly lengthened treatment cycles for patients with resectable tumors, offsetting the impact of declining unit prices. Global PD-1 and PD-L1 usage is projected to exceed 1 billion patient-treatments by 2028; however, due to competition from biosimilars, sales revenue may see only modest growth, compelling innovative companies to rely on overseas expansion and combination patent strategies to sustain profitability.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global PD-1 and PD-L1 Monoclonal Antibodies market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Target and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Merck & Co., Inc. (US)
Bristol Myers Squibb Company (US)
F. Hoffmann-La Roche Ltd (CH)
Merck KGaA (DE)
AstraZeneca plc (GB)
Regeneron Pharmaceuticals, Inc. (US)
GSK plc (GB)
Incyte Corporation (US)
BIOCAD JSC (RU)
BeOne Medicines Ltd. (CH)
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN)
Innovent Biologics, Inc. (CN)
Shanghai Junshi Biosciences Co., Ltd. (CN)
Shanghai Henlius Biotech, Inc. (CN)
Segment by Target
PD-1 Monoclonal Antibody
PD-L1 Monoclonal Antibody
Segment by Antibody Origin
Fully Human
Humanized
Segment by Dosing Interval
Every 2 Weeks (Q2W)
Every 3 Weeks (Q3W)
Every 4 Weeks or Longer (≥Q4W)
Segment by Application
Lung Cancer Treatment
Melanoma Treatment
Bowel Cancer Treatment
Other
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the PD-1 and PD-L1 Monoclonal Antibodies study scope, segments the market by Target and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to PD-1 and PD-L1 Monoclonal Antibodies: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Target
1.2.1 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target, 2021 vs 2025 vs 2032
1.2.2 PD-1 Monoclonal Antibody
1.2.3 PD-L1 Monoclonal Antibody
1.3 Market Segmentation by Antibody Origin
1.3.1 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin, 2021 vs 2025 vs 2032
1.3.2 Fully Human
1.3.3 Humanized
1.4 Market Segmentation by Dosing Interval
1.4.1 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval, 2021 vs 2025 vs 2032
1.4.2 Every 2 Weeks (Q2W)
1.4.3 Every 3 Weeks (Q3W)
1.4.4 Every 4 Weeks or Longer (≥Q4W)
1.5 Market Segmentation by Application
1.5.1 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Lung Cancer Treatment
1.5.3 Melanoma Treatment
1.5.4 Bowel Cancer Treatment
1.5.5 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Estimates and Forecasts (2021-2032)
2.2 Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competitive Landscape
3.1 Global PD-1 and PD-L1 Monoclonal Antibodies Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global PD-1 and PD-L1 Monoclonal Antibodies Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 PD-1 Monoclonal Antibody: Market Share by Key Players
3.3.2 PD-L1 Monoclonal Antibody: Market Share by Key Players
3.4 Global PD-1 and PD-L1 Monoclonal Antibodies Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Product Segmentation
4.1 Global PD-1 and PD-L1 Monoclonal Antibodies Market by Target
4.1.1 Global Revenue by Target (2021-2032)
4.1.2 Global Revenue-Based Market Share by Target (2021-2032)
4.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market by Antibody Origin
4.2.1 Global Revenue by Antibody Origin (2021-2032)
4.2.2 Global Revenue-Based Market Share by Antibody Origin (2021-2032)
4.3 Global PD-1 and PD-L1 Monoclonal Antibodies Market by Dosing Interval
4.3.1 Global Revenue by Dosing Interval (2021-2032)
4.3.2 Global Revenue-Based Market Share by Dosing Interval (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico
7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa
11 Corporate Profile
11.1 Merck & Co., Inc. (US)
11.1.1 Merck & Co., Inc. (US) Corporation Information
11.1.2 Merck & Co., Inc. (US) Business Overview
11.1.3 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.1.4 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.1.5 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Product in 2025
11.1.6 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Application in 2025
11.1.7 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Geographic Area in 2025
11.1.8 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
11.1.9 Merck & Co., Inc. (US) Recent Developments
11.2 Bristol Myers Squibb Company (US)
11.2.1 Bristol Myers Squibb Company (US) Corporation Information
11.2.2 Bristol Myers Squibb Company (US) Business Overview
11.2.3 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.2.4 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.2.5 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Product in 2025
11.2.6 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Application in 2025
11.2.7 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Geographic Area in 2025
11.2.8 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
11.2.9 Bristol Myers Squibb Company (US) Recent Developments
11.3 F. Hoffmann-La Roche Ltd (CH)
11.3.1 F. Hoffmann-La Roche Ltd (CH) Corporation Information
11.3.2 F. Hoffmann-La Roche Ltd (CH) Business Overview
11.3.3 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.3.4 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.3.5 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Product in 2025
11.3.6 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Application in 2025
11.3.7 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Geographic Area in 2025
11.3.8 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
11.3.9 F. Hoffmann-La Roche Ltd (CH) Recent Developments
11.4 Merck KGaA (DE)
11.4.1 Merck KGaA (DE) Corporation Information
11.4.2 Merck KGaA (DE) Business Overview
11.4.3 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.4.4 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.4.5 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Product in 2025
11.4.6 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Application in 2025
11.4.7 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Geographic Area in 2025
11.4.8 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
11.4.9 Merck KGaA (DE) Recent Developments
11.5 AstraZeneca plc (GB)
11.5.1 AstraZeneca plc (GB) Corporation Information
11.5.2 AstraZeneca plc (GB) Business Overview
11.5.3 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.5.4 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.5.5 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Product in 2025
11.5.6 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Application in 2025
11.5.7 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue by Geographic Area in 2025
11.5.8 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
11.5.9 AstraZeneca plc (GB) Recent Developments
11.6 Regeneron Pharmaceuticals, Inc. (US)
11.6.1 Regeneron Pharmaceuticals, Inc. (US) Corporation Information
11.6.2 Regeneron Pharmaceuticals, Inc. (US) Business Overview
11.6.3 Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.6.4 Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.6.5 Regeneron Pharmaceuticals, Inc. (US) Recent Developments
11.7 GSK plc (GB)
11.7.1 GSK plc (GB) Corporation Information
11.7.2 GSK plc (GB) Business Overview
11.7.3 GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.7.4 GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.7.5 GSK plc (GB) Recent Developments
11.8 Incyte Corporation (US)
11.8.1 Incyte Corporation (US) Corporation Information
11.8.2 Incyte Corporation (US) Business Overview
11.8.3 Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.8.4 Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.8.5 Incyte Corporation (US) Recent Developments
11.9 BIOCAD JSC (RU)
11.9.1 BIOCAD JSC (RU) Corporation Information
11.9.2 BIOCAD JSC (RU) Business Overview
11.9.3 BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.9.4 BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.9.5 BIOCAD JSC (RU) Recent Developments
11.10 BeOne Medicines Ltd. (CH)
11.10.1 BeOne Medicines Ltd. (CH) Corporation Information
11.10.2 BeOne Medicines Ltd. (CH) Business Overview
11.10.3 BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.10.4 BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN)
11.11.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Corporation Information
11.11.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Business Overview
11.11.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.11.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.11.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Recent Developments
11.12 Innovent Biologics, Inc. (CN)
11.12.1 Innovent Biologics, Inc. (CN) Corporation Information
11.12.2 Innovent Biologics, Inc. (CN) Business Overview
11.12.3 Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.12.4 Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.12.5 Innovent Biologics, Inc. (CN) Recent Developments
11.13 Shanghai Junshi Biosciences Co., Ltd. (CN)
11.13.1 Shanghai Junshi Biosciences Co., Ltd. (CN) Corporation Information
11.13.2 Shanghai Junshi Biosciences Co., Ltd. (CN) Business Overview
11.13.3 Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.13.4 Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.13.5 Shanghai Junshi Biosciences Co., Ltd. (CN) Recent Developments
11.14 Shanghai Henlius Biotech, Inc. (CN)
11.14.1 Shanghai Henlius Biotech, Inc. (CN) Corporation Information
11.14.2 Shanghai Henlius Biotech, Inc. (CN) Business Overview
11.14.3 Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Features and Attributes
11.14.4 Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
11.14.5 Shanghai Henlius Biotech, Inc. (CN) Recent Developments
12 PD-1 and PD-L1 Monoclonal Antibodies Value Chain and Ecosystem Analysis
12.1 PD-1 and PD-L1 Monoclonal Antibodies Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 PD-1 and PD-L1 Monoclonal Antibodies Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global PD-1 and PD-L1 Monoclonal Antibodies Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate by Target, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate by Antibody Origin, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate by Dosing Interval, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region (US$ Million), 2021-2026
Table 7. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Players (US$ Million), 2021-2026
Table 10. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on PD-1 and PD-L1 Monoclonal Antibodies Revenue, 2025
Table 13. Global PD-1 and PD-L1 Monoclonal Antibodies Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global PD-1 and PD-L1 Monoclonal Antibodies Companies Headquarters
Table 15. Global PD-1 and PD-L1 Monoclonal Antibodies Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Target (US$ Million), 2021-2026
Table 19. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Target (US$ Million), 2027-2032
Table 20. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Antibody Origin (US$ Million), 2021-2026
Table 21. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Antibody Origin (US$ Million), 2027-2032
Table 22. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Dosing Interval (US$ Million), 2021-2026
Table 23. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Dosing Interval (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Application (US$ Million), 2021-2026
Table 26. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Application (US$ Million), 2027-2032
Table 27. PD-1 and PD-L1 Monoclonal Antibodies High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America PD-1 and PD-L1 Monoclonal Antibodies Growth Accelerators and Market Barriers
Table 31. North America PD-1 and PD-L1 Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe PD-1 and PD-L1 Monoclonal Antibodies Growth Accelerators and Market Barriers
Table 33. Europe PD-1 and PD-L1 Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Growth Accelerators and Market Barriers
Table 35. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America PD-1 and PD-L1 Monoclonal Antibodies Investment Opportunities and Key Challenges
Table 37. Central and South America PD-1 and PD-L1 Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Investment Opportunities and Key Challenges
Table 39. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Merck & Co., Inc. (US) Corporation Information
Table 41. Merck & Co., Inc. (US) Description and Major Businesses
Table 42. Merck & Co., Inc. (US) Product Features and Attributes
Table 43. Merck & Co., Inc. (US) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Merck & Co., Inc. (US) Revenue Proportion by Product in 2025
Table 45. Merck & Co., Inc. (US) Revenue Proportion by Application in 2025
Table 46. Merck & Co., Inc. (US) Revenue Proportion by Geographic Area in 2025
Table 47. Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
Table 48. Merck & Co., Inc. (US) Recent Developments
Table 49. Bristol Myers Squibb Company (US) Corporation Information
Table 50. Bristol Myers Squibb Company (US) Description and Major Businesses
Table 51. Bristol Myers Squibb Company (US) Product Features and Attributes
Table 52. Bristol Myers Squibb Company (US) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Bristol Myers Squibb Company (US) Revenue Proportion by Product in 2025
Table 54. Bristol Myers Squibb Company (US) Revenue Proportion by Application in 2025
Table 55. Bristol Myers Squibb Company (US) Revenue Proportion by Geographic Area in 2025
Table 56. Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
Table 57. Bristol Myers Squibb Company (US) Recent Developments
Table 58. F. Hoffmann-La Roche Ltd (CH) Corporation Information
Table 59. F. Hoffmann-La Roche Ltd (CH) Description and Major Businesses
Table 60. F. Hoffmann-La Roche Ltd (CH) Product Features and Attributes
Table 61. F. Hoffmann-La Roche Ltd (CH) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. F. Hoffmann-La Roche Ltd (CH) Revenue Proportion by Product in 2025
Table 63. F. Hoffmann-La Roche Ltd (CH) Revenue Proportion by Application in 2025
Table 64. F. Hoffmann-La Roche Ltd (CH) Revenue Proportion by Geographic Area in 2025
Table 65. F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
Table 66. F. Hoffmann-La Roche Ltd (CH) Recent Developments
Table 67. Merck KGaA (DE) Corporation Information
Table 68. Merck KGaA (DE) Description and Major Businesses
Table 69. Merck KGaA (DE) Product Features and Attributes
Table 70. Merck KGaA (DE) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Merck KGaA (DE) Revenue Proportion by Product in 2025
Table 72. Merck KGaA (DE) Revenue Proportion by Application in 2025
Table 73. Merck KGaA (DE) Revenue Proportion by Geographic Area in 2025
Table 74. Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
Table 75. Merck KGaA (DE) Recent Developments
Table 76. AstraZeneca plc (GB) Corporation Information
Table 77. AstraZeneca plc (GB) Description and Major Businesses
Table 78. AstraZeneca plc (GB) Product Features and Attributes
Table 79. AstraZeneca plc (GB) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. AstraZeneca plc (GB) Revenue Proportion by Product in 2025
Table 81. AstraZeneca plc (GB) Revenue Proportion by Application in 2025
Table 82. AstraZeneca plc (GB) Revenue Proportion by Geographic Area in 2025
Table 83. AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies SWOT Analysis
Table 84. AstraZeneca plc (GB) Recent Developments
Table 85. Regeneron Pharmaceuticals, Inc. (US) Corporation Information
Table 86. Regeneron Pharmaceuticals, Inc. (US) Description and Major Businesses
Table 87. Regeneron Pharmaceuticals, Inc. (US) Product Features and Attributes
Table 88. Regeneron Pharmaceuticals, Inc. (US) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Regeneron Pharmaceuticals, Inc. (US) Recent Developments
Table 90. GSK plc (GB) Corporation Information
Table 91. GSK plc (GB) Description and Major Businesses
Table 92. GSK plc (GB) Product Features and Attributes
Table 93. GSK plc (GB) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. GSK plc (GB) Recent Developments
Table 95. Incyte Corporation (US) Corporation Information
Table 96. Incyte Corporation (US) Description and Major Businesses
Table 97. Incyte Corporation (US) Product Features and Attributes
Table 98. Incyte Corporation (US) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Incyte Corporation (US) Recent Developments
Table 100. BIOCAD JSC (RU) Corporation Information
Table 101. BIOCAD JSC (RU) Description and Major Businesses
Table 102. BIOCAD JSC (RU) Product Features and Attributes
Table 103. BIOCAD JSC (RU) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. BIOCAD JSC (RU) Recent Developments
Table 105. BeOne Medicines Ltd. (CH) Corporation Information
Table 106. BeOne Medicines Ltd. (CH) Description and Major Businesses
Table 107. BeOne Medicines Ltd. (CH) Product Features and Attributes
Table 108. BeOne Medicines Ltd. (CH) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. BeOne Medicines Ltd. (CH) Recent Developments
Table 110. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Corporation Information
Table 111. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Description and Major Businesses
Table 112. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Product Features and Attributes
Table 113. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Recent Developments
Table 115. Innovent Biologics, Inc. (CN) Corporation Information
Table 116. Innovent Biologics, Inc. (CN) Description and Major Businesses
Table 117. Innovent Biologics, Inc. (CN) Product Features and Attributes
Table 118. Innovent Biologics, Inc. (CN) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Innovent Biologics, Inc. (CN) Recent Developments
Table 120. Shanghai Junshi Biosciences Co., Ltd. (CN) Corporation Information
Table 121. Shanghai Junshi Biosciences Co., Ltd. (CN) Description and Major Businesses
Table 122. Shanghai Junshi Biosciences Co., Ltd. (CN) Product Features and Attributes
Table 123. Shanghai Junshi Biosciences Co., Ltd. (CN) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Shanghai Junshi Biosciences Co., Ltd. (CN) Recent Developments
Table 125. Shanghai Henlius Biotech, Inc. (CN) Corporation Information
Table 126. Shanghai Henlius Biotech, Inc. (CN) Description and Major Businesses
Table 127. Shanghai Henlius Biotech, Inc. (CN) Product Features and Attributes
Table 128. Shanghai Henlius Biotech, Inc. (CN) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Shanghai Henlius Biotech, Inc. (CN) Recent Developments
Table 130. Technologies, Platforms and Infrastructure
Table 131. Distributors List
Table 132. Market Trends and Market Evolution
Table 133. Market Drivers and Opportunities
Table 134. Market Challenges, Risks, and Restraints
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources


List of Figures
Figure 1. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate by Target, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. PD-1 Monoclonal Antibody Product Picture
Figure 3. PD-L1 Monoclonal Antibody Product Picture
Figure 4. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate by Antibody Origin, 2021 vs 2025 vs 2032 (US$ Million)
Figure 5. Fully Human Product Picture
Figure 6. Humanized Product Picture
Figure 7. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate by Dosing Interval, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Every 2 Weeks (Q2W) Product Picture
Figure 9. Every 3 Weeks (Q3W) Product Picture
Figure 10. Every 4 Weeks or Longer (≥Q4W) Product Picture
Figure 11. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Lung Cancer Treatment
Figure 13. Melanoma Treatment
Figure 14. Bowel Cancer Treatment
Figure 15. Other
Figure 16. PD-1 and PD-L1 Monoclonal Antibodies Report Years Considered
Figure 17. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 19. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 20. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue-Based Market Share by Region (2021-2032)
Figure 21. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue-Based Market Share Ranking (2025)
Figure 22. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 23. PD-1 Monoclonal Antibody Revenue-Based Market Share by Player in 2025
Figure 24. PD-L1 Monoclonal Antibody Revenue-Based Market Share by Player in 2025
Figure 25. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue-Based Market Share by Target (2021-2032)
Figure 26. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue-Based Market Share by Antibody Origin (2021-2032)
Figure 27. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue-Based Market Share by Dosing Interval (2021-2032)
Figure 28. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue-Based Market Share by Application (2021-2032)
Figure 29. North America PD-1 and PD-L1 Monoclonal Antibodies Revenue YoY (US$ Million), 2021-2032
Figure 30. North America Top 5 Players PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) in 2025
Figure 31. North America PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) by Application (2021-2032)
Figure 32. US PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 33. Canada PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 34. Mexico PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 35. Europe PD-1 and PD-L1 Monoclonal Antibodies Revenue YoY (US$ Million), 2021-2032
Figure 36. Europe Top 5 Players PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) in 2025
Figure 37. Europe PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) by Application (2021-2032)
Figure 38. Germany PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 39. France PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 40. U.K. PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 41. Italy PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 42. Russia PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 43. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Revenue YoY (US$ Million), 2021-2032
Figure 44. Asia-Pacific Top 8 Players PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) in 2025
Figure 45. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) by Application (2021-2032)
Figure 46. Indonesia PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 47. Japan PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 48. South Korea PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 49. Australia PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 50. India PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 51. Indonesia PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 52. Vietnam PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 53. Malaysia PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 54. Philippines PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 55. Singapore PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 56. Central and South America PD-1 and PD-L1 Monoclonal Antibodies Revenue YoY (US$ Million), 2021-2032
Figure 57. Central and South America Top 5 Players PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) in 2025
Figure 58. Central and South America PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) by Application (2021-2032)
Figure 59. Brazil PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 60. Argentina PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 61. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Revenue YoY (US$ Million), 2021-2032
Figure 62. Middle East and Africa Top 5 Players PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) in 2025
Figure 63. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million) by Application (2021-2032)
Figure 64. GCC Countries PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 65. Israel PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 66. Egypt PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 67. South Africa PD-1 and PD-L1 Monoclonal Antibodies Revenue (US$ Million), 2021-2032
Figure 68. PD-1 and PD-L1 Monoclonal Antibodies Value Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed